Pds biotech announces final topline survival data from versatile-002 phase 2 trial in head and neck cancer

Median overall survival (mos) of 39.3 months in patients with cps ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*

PDSB Ratings Summary

PDSB Quant Ranking